It controls CD47 and PD-L1 expression in diverse tumor cells, impacting immune checkpoint pathways; the overexpression of these molecules driven by Myc inhibits both innate and adaptive immune responses, thereby promoting tumor progression [91]. This evidence concerns the gene CD47 and neoplasm.